Author

Todd A. Black

TB Alliance

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:mouse· 4 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

Robert H. BatesiD· 3 shared Alessia Tagliavini· 2 shared Anna M. UptoniD· 2 shared Cécile PascaliD· 2 shared Chiara RoversiiD· 2 shared Clara Aguilar-PéreziD· 2 shared David J. Hermann· 2 shared Debra Flood· 2 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Robert H. BatesORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

DDU384: A new preclinical candidate for the treatment of Tuberculosis

Simon R. Green, Kirsteen I. Buchanan, Helena I. Boshoff, Paul J. Koovits, Dinakaran Murugesan, Cristina De Cozar-Gallardo, Ana Yepes, Eik Hoffmann, Lisa M. Massoudi, Paul J. Converse, Oliver D. Komm, Laura Guijarro-López, Patricia Casado, Paul Scullion, Adolfo García-Pérez, , Laura A. T. Cleghorn

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

bioRxiv · Oct 27, 2026 · PreprintMicrobiology

Next Generation TB Drug Combinations from the Pan-TB Consortium: Combination Efficacy and Contributions of Individual Agents, Evaluated in a BALB/c Mouse TB Model

Sylvie Sordello, Alain Le Coupanec, Zoï Vahlas, Chiara Roversi, ROBERTO VISENTIN, Xavier Boulenc, Denise Federico, Simone Zannoni, Simone Modolo, Augusto Celon, Roberto Petterlini, Cécile Pascal, Fanny Deglave, Alessia Tagliavini, Marco Pergher, , Anna M. Upton

The paper evaluates next-generation TB drug combinations in a mouse model, showing some regimens cure 90% of mice in under 2 months with faster sterilizing efficacy than existing treatments.

bioRxiv · Jun 23, 2026 · PreprintPharmacology & Toxicology

Nonclinical pharmacokinetics and relative efficacy of the first 25 novel tuberculosis drug combinations from the PAN-TB consortium: Use of the BALB/c relapsing mouse model and combination pharmacokinetics within a modeling-based framework

Sylvie Sordello, Alessia Tagliavini, Xavier Boulenc, Laure Brock, Simone Zannoni, Chiara Roversi, ROBERTO VISENTIN, Darren Metcalf, Denise Federico, Simone Modolo, Giulia Calusi, Roberto Petterlini, Guillaume R. Golovkine, Cécile Pascal, Emilie Huc‐Claustre, , Anna M. Upton

The paper evaluates 25 tuberculosis drug combinations in a mouse model, finding 15 combinations with T90 <5 months and three top combinations curing 90% of mice in <3 months.

bioRxiv · May 7, 2026 · PreprintMicrobiology

Contribution of telacebec to novel drug regimens in a murine tuberculosis model

Oliver D. Komm, Sandeep K. Tyagi, Andrew Jesse Garcia, Deepak V. Almeida, Yong Seok Chang, Si‐Yang Li, Jennie Ruelas Castillo, Paul J. Converse, Todd A. Black, Nader Fotouhi, Eric L. Nuermberger

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

Antimicrobial Agents and Chemotherapy · Dec 9, 2024Peer-reviewedMicrobiology